Log in to Thinknum

Interested in Thinknum?

Request a demo
CR

Curis

- NASDAQ:CRIS
Last Updated 2019-05-21

LinkedIn Profile

Access Curis historical Linkedin company profile data on number of followers, employee headcount and more

Records

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Ticker Sector Ticker Industry
nasdaq:cris 73424 May 5th, 2019 12:00AM Curis 2.7K 95.00 Open Biotechnology May 5th, 2019 03:32PM May 5th, 2019 03:32PM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis’s pipeline of drug candidates includes CUDC-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently being tested in a Phase 1 trial in patients with lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. Our corporate culture is focused on learning and growing in a challenging environment with a committed group of peers working together as a team. For more information, visit Curis'​ website at www.curis.com. Open Drug Development, Oncology, Small molecule, Immunology Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 May 4th, 2019 12:00AM Curis 2.7K 95.00 Open Biotechnology May 3rd, 2019 10:17PM May 3rd, 2019 10:17PM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis’s pipeline of drug candidates includes CUDC-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently being tested in a Phase 1 trial in patients with lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. Our corporate culture is focused on learning and growing in a challenging environment with a committed group of peers working together as a team. For more information, visit Curis'​ website at www.curis.com. Open Drug Development, Oncology, Small molecule, Immunology Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 May 3rd, 2019 12:00AM Curis 2.7K 94.00 Open Biotechnology May 3rd, 2019 11:52AM May 3rd, 2019 11:52AM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis’s pipeline of drug candidates includes CUDC-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently being tested in a Phase 1 trial in patients with lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. Our corporate culture is focused on learning and growing in a challenging environment with a committed group of peers working together as a team. For more information, visit Curis'​ website at www.curis.com. Open Drug Development, Oncology, Small molecule, Immunology Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 May 2nd, 2019 12:00AM Curis 2.7K 93.00 Open Biotechnology May 2nd, 2019 11:54AM May 2nd, 2019 11:54AM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis’s pipeline of drug candidates includes CUDC-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently being tested in a Phase 1 trial in patients with lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. Our corporate culture is focused on learning and growing in a challenging environment with a committed group of peers working together as a team. For more information, visit Curis'​ website at www.curis.com. Open Drug Development, Oncology, Small molecule, Immunology Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 May 1st, 2019 12:00AM Curis 2.7K 93.00 Open Biotechnology May 1st, 2019 08:36AM May 1st, 2019 08:36AM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis’s pipeline of drug candidates includes CUDC-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently being tested in a Phase 1 trial in patients with lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. Our corporate culture is focused on learning and growing in a challenging environment with a committed group of peers working together as a team. For more information, visit Curis'​ website at www.curis.com. Open Drug Development, Oncology, Small molecule, Immunology Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Apr 30th, 2019 12:00AM Curis 2.7K 93.00 Open Biotechnology Apr 30th, 2019 12:21PM Apr 30th, 2019 12:21PM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis’s pipeline of drug candidates includes CUDC-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently being tested in a Phase 1 trial in patients with lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. Our corporate culture is focused on learning and growing in a challenging environment with a committed group of peers working together as a team. For more information, visit Curis'​ website at www.curis.com. Open Drug Development, Oncology, Small molecule, Immunology Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Apr 29th, 2019 12:00AM Curis 2.7K 94.00 Open Biotechnology Apr 28th, 2019 10:17PM Apr 28th, 2019 10:17PM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis’s pipeline of drug candidates includes CUDC-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently being tested in a Phase 1 trial in patients with lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. Our corporate culture is focused on learning and growing in a challenging environment with a committed group of peers working together as a team. For more information, visit Curis'​ website at www.curis.com. Open Drug Development, Oncology, Small molecule, Immunology Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Apr 28th, 2019 12:00AM Curis 2.7K 94.00 Open Biotechnology Apr 28th, 2019 10:38AM Apr 28th, 2019 10:38AM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis’s pipeline of drug candidates includes CUDC-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently being tested in a Phase 1 trial in patients with lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. Our corporate culture is focused on learning and growing in a challenging environment with a committed group of peers working together as a team. For more information, visit Curis'​ website at www.curis.com. Open Drug Development, Oncology, Small molecule, Immunology Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Apr 27th, 2019 12:00AM Curis 2.7K 94.00 Open Biotechnology Apr 27th, 2019 01:11PM Apr 27th, 2019 01:11PM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis’s pipeline of drug candidates includes CUDC-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently being tested in a Phase 1 trial in patients with lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. Our corporate culture is focused on learning and growing in a challenging environment with a committed group of peers working together as a team. For more information, visit Curis'​ website at www.curis.com. Open Drug Development, Oncology, Small molecule, Immunology Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology
nasdaq:cris 73424 Apr 26th, 2019 12:00AM Curis 2.7K 94.00 Open Biotechnology Apr 26th, 2019 02:08PM Apr 26th, 2019 02:08PM Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis’s pipeline of drug candidates includes CUDC-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently being tested in a Phase 1 trial in patients with lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. Our corporate culture is focused on learning and growing in a challenging environment with a committed group of peers working together as a team. For more information, visit Curis'​ website at www.curis.com. Open Drug Development, Oncology, Small molecule, Immunology Open 4 Maguire Rd. Lexington MA US Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.